vs

Side-by-side financial comparison of INGLES MARKETS INC (IMKTA) and Insulet Corporation (PODD). Click either name above to swap in a different company.

INGLES MARKETS INC is the larger business by last-quarter revenue ($1.4B vs $761.7M, roughly 1.8× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs 2.0%, a 9.9% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 6.6%). Insulet Corporation produced more free cash flow last quarter ($89.5M vs $2.1M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 0.2%).

Ingles Markets, Inc. is an American supermarket chain based in Black Mountain, North Carolina. As of September 2021, the company operates 198 supermarkets in the Appalachian region of the Southeastern United States. The company is listed on the NASDAQ under the ticker symbol IMKTA and is part of the Global Select Market tier of trading.

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.

IMKTA vs PODD — Head-to-Head

Bigger by revenue
IMKTA
IMKTA
1.8× larger
IMKTA
$1.4B
$761.7M
PODD
Growing faster (revenue YoY)
PODD
PODD
+27.3% gap
PODD
33.9%
6.6%
IMKTA
Higher net margin
PODD
PODD
9.9% more per $
PODD
12.0%
2.0%
IMKTA
More free cash flow
PODD
PODD
$87.4M more FCF
PODD
$89.5M
$2.1M
IMKTA
Faster 2-yr revenue CAGR
PODD
PODD
Annualised
PODD
24.9%
0.2%
IMKTA

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
IMKTA
IMKTA
PODD
PODD
Revenue
$1.4B
$761.7M
Net Profit
$28.1M
$91.1M
Gross Margin
24.4%
69.5%
Operating Margin
2.9%
16.0%
Net Margin
2.0%
12.0%
Revenue YoY
6.6%
33.9%
Net Profit YoY
69.6%
157.3%
EPS (diluted)
$1.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMKTA
IMKTA
PODD
PODD
Q1 26
$761.7M
Q4 25
$1.4B
$783.7M
Q3 25
$1.4B
$706.3M
Q2 25
$1.3B
$649.1M
Q1 25
$1.3B
$569.0M
Q4 24
$1.3B
$597.5M
Q3 24
$1.4B
$543.9M
Q2 24
$1.4B
$488.5M
Net Profit
IMKTA
IMKTA
PODD
PODD
Q1 26
$91.1M
Q4 25
$28.1M
$101.6M
Q3 25
$25.7M
$87.6M
Q2 25
$26.2M
$22.5M
Q1 25
$15.1M
$35.4M
Q4 24
$16.6M
$100.7M
Q3 24
$-1.5M
$77.5M
Q2 24
$31.7M
$188.6M
Gross Margin
IMKTA
IMKTA
PODD
PODD
Q1 26
69.5%
Q4 25
24.4%
72.6%
Q3 25
24.5%
72.2%
Q2 25
24.3%
69.7%
Q1 25
23.4%
71.9%
Q4 24
23.4%
72.1%
Q3 24
21.4%
69.3%
Q2 24
23.7%
67.7%
Operating Margin
IMKTA
IMKTA
PODD
PODD
Q1 26
16.0%
Q4 25
2.9%
18.7%
Q3 25
2.6%
16.7%
Q2 25
2.8%
18.7%
Q1 25
1.6%
15.6%
Q4 24
1.8%
18.3%
Q3 24
-0.1%
16.2%
Q2 24
3.2%
11.2%
Net Margin
IMKTA
IMKTA
PODD
PODD
Q1 26
12.0%
Q4 25
2.0%
13.0%
Q3 25
1.9%
12.4%
Q2 25
1.9%
3.5%
Q1 25
1.1%
6.2%
Q4 24
1.3%
16.9%
Q3 24
-0.1%
14.2%
Q2 24
2.3%
38.6%
EPS (diluted)
IMKTA
IMKTA
PODD
PODD
Q1 26
$1.30
Q4 25
$1.42
Q3 25
$1.24
Q2 25
$0.32
Q1 25
$0.50
Q4 24
$1.38
Q3 24
$1.08
Q2 24
$2.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMKTA
IMKTA
PODD
PODD
Cash + ST InvestmentsLiquidity on hand
$480.4M
Total DebtLower is stronger
$18.6M
Stockholders' EquityBook value
$1.6B
$1.3B
Total Assets
$2.6B
$3.0B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMKTA
IMKTA
PODD
PODD
Q1 26
$480.4M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Total Debt
IMKTA
IMKTA
PODD
PODD
Q1 26
$18.6M
Q4 25
$930.8M
Q3 25
$514.8M
$934.9M
Q2 25
$939.0M
Q1 25
$1.6B
Q4 24
$1.3B
Q3 24
$532.6M
$1.4B
Q2 24
$1.4B
Stockholders' Equity
IMKTA
IMKTA
PODD
PODD
Q1 26
$1.3B
Q4 25
$1.6B
$1.5B
Q3 25
$1.6B
$1.4B
Q2 25
$1.6B
$1.5B
Q1 25
$1.6B
$1.3B
Q4 24
$1.6B
$1.2B
Q3 24
$1.5B
$1.1B
Q2 24
$1.6B
$998.4M
Total Assets
IMKTA
IMKTA
PODD
PODD
Q1 26
$3.0B
Q4 25
$2.6B
$3.2B
Q3 25
$2.6B
$3.0B
Q2 25
$2.5B
$3.5B
Q1 25
$2.5B
$3.5B
Q4 24
$2.5B
$3.1B
Q3 24
$2.5B
$3.0B
Q2 24
$2.5B
$2.9B
Debt / Equity
IMKTA
IMKTA
PODD
PODD
Q1 26
0.01×
Q4 25
0.61×
Q3 25
0.32×
0.68×
Q2 25
0.64×
Q1 25
1.21×
Q4 24
1.07×
Q3 24
0.34×
1.21×
Q2 24
1.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMKTA
IMKTA
PODD
PODD
Operating Cash FlowLast quarter
$38.4M
$113.8M
Free Cash FlowOCF − Capex
$2.1M
$89.5M
FCF MarginFCF / Revenue
0.1%
11.8%
Capex IntensityCapex / Revenue
2.6%
3.2%
Cash ConversionOCF / Net Profit
1.37×
1.25×
TTM Free Cash FlowTrailing 4 quarters
$123.1M
$415.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMKTA
IMKTA
PODD
PODD
Q1 26
$113.8M
Q4 25
$38.4M
$183.3M
Q3 25
$59.9M
$125.7M
Q2 25
$74.8M
$196.5M
Q1 25
$63.1M
$63.8M
Q4 24
$-43.6M
$147.7M
Q3 24
$73.3M
$98.5M
Q2 24
$103.3M
$96.5M
Free Cash Flow
IMKTA
IMKTA
PODD
PODD
Q1 26
$89.5M
Q4 25
$2.1M
$48.2M
Q3 25
$36.8M
$100.1M
Q2 25
$45.4M
$177.9M
Q1 25
$38.9M
$51.5M
Q4 24
$-81.4M
$94.1M
Q3 24
$5.4M
$71.8M
Q2 24
$58.6M
$74.0M
FCF Margin
IMKTA
IMKTA
PODD
PODD
Q1 26
11.8%
Q4 25
0.1%
6.2%
Q3 25
2.7%
14.2%
Q2 25
3.4%
27.4%
Q1 25
2.9%
9.1%
Q4 24
-6.3%
15.7%
Q3 24
0.4%
13.2%
Q2 24
4.2%
15.1%
Capex Intensity
IMKTA
IMKTA
PODD
PODD
Q1 26
3.2%
Q4 25
2.6%
17.2%
Q3 25
1.7%
3.6%
Q2 25
2.2%
2.9%
Q1 25
1.8%
2.2%
Q4 24
2.9%
9.0%
Q3 24
4.9%
4.9%
Q2 24
3.2%
4.6%
Cash Conversion
IMKTA
IMKTA
PODD
PODD
Q1 26
1.25×
Q4 25
1.37×
1.80×
Q3 25
2.33×
1.43×
Q2 25
2.85×
8.73×
Q1 25
4.17×
1.80×
Q4 24
-2.63×
1.47×
Q3 24
1.27×
Q2 24
3.26×
0.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMKTA
IMKTA

Grocery$502.1M37%
Perishables$359.7M26%
Non Foods$305.5M22%
Gasoline$152.1M11%
Other$53.6M4%

PODD
PODD

Omnipod$515.6M68%
International Omnipod$242.9M32%
Drug Delivery$3.3M0%

Related Comparisons